# A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes

> **NCT04353817** · PHASE3 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 121 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** ELX/TEZ/IVA
- **DRUG:** IVA
- **OTHER:** Placebo (matched to ELX/TEZ/IVA)
- **OTHER:** Placebo (matched to IVA)

## Key facts

- **NCT ID:** NCT04353817
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-19
- **Primary completion:** 2021-05-17
- **Final completion:** 2021-05-17
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2022-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04353817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04353817, "A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04353817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*